New PDUFA date set for Spectrum's Fusilev for colorectal cancer
This article was originally published in Scrip
Executive Summary
The US FDA has accepted for filing and review Spectrum Pharmaceuticals' response to the agency's previous complete response letter regarding the supplemental NDA (sNDA) for the company's drug Fusilev (levoleucovorin) for the treatment of patients with metastatic colorectal cancer (mCRC).